<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Genomics Inf</journal-id>
      <journal-id journal-id-type="iso-abbrev">Genomics Inf</journal-id>
      <journal-id journal-id-type="publisher-id">GNI</journal-id>
      <journal-title-group>
        <journal-title>Genomics &amp; Informatics</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1598-866X</issn>
      <issn pub-type="epub">2234-0742</issn>
      <publisher>
        <publisher-name>Korea Genome Organization</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23105933</article-id>
      <article-id pub-id-type="pmc">3480681</article-id>
      <article-id pub-id-type="doi">10.5808/GI.2012.10.2.74</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Alternative Splicing and Its Impact as a Cancer Diagnostic Marker</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Yun-Ji</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Kim</surname>
            <given-names>Heui-Soo</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
      </contrib-group>
      <aff id="A1">Department of Biological Sciences, College of Natural Sciences, Pusan National University, Busan 609-735, Korea.</aff>
      <author-notes>
        <corresp>Corresponding author: Tel: +82-51-510-2259, Fax: +82-51-581-2962, <email>khs307@pusan.ac.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>30</day>
        <month>6</month>
        <year>2012</year>
      </pub-date>
      <volume>10</volume>
      <issue>2</issue>
      <fpage>74</fpage>
      <lpage>80</lpage>
      <history>
        <date date-type="received">
          <day>01</day>
          <month>5</month>
          <year>2012</year>
        </date>
        <date date-type="rev-recd">
          <day>18</day>
          <month>5</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>5</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2012 by The Korea Genome Organization</copyright-statement>
        <copyright-year>2012</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">
          <license-p>It is identical to the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Most genes are processed by alternative splicing for gene expression, resulting in the complexity of the transcriptome in eukaryotes. It allows a limited number of genes to encode various proteins with intricate functions. Alternative splicing is regulated by genetic mutations in cis-regulatory factors and epigenetic events. Furthermore, splicing events occur differently according to cell type, developmental stage, and various diseases, including cancer. Genome instability and flexible proteomes by alternative splicing could affect cancer cells to grow and survive, leading to metastasis. Cancer cells that are transformed by aberrant and uncontrolled mechanisms could produce alternative splicing to maintain and spread them continuously. Splicing variants in various cancers represent crucial roles for tumorigenesis. Taken together, the identification of alternative spliced variants as biomarkers to distinguish between normal and cancer cells could cast light on tumorigenesis.</p>
      </abstract>
      <kwd-group>
        <kwd>alternative splicing</kwd>
        <kwd>biological markers</kwd>
        <kwd>neoplasms</kwd>
        <kwd>neoplastic cell transformation</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Introduction</title>
      <p>Genes are transcribed into pre-mRNA and pass through splicing as a post-transcriptional modification to generate mature mRNA for translation [<xref ref-type="bibr" rid="B1">1</xref>]. Splicing is an essential process for gene expression in eukaryotes, eliminating introns and joining the exons, which occurs in the spliceosome, a complex of small nuclear ribonucleoproteins (snRNPs) and other proteins [<xref ref-type="bibr" rid="B2">2</xref>]. This splicing can generate alternative spliced transcripts from pre-mRNA and different exon constitutions, resulting in different proteins. Alternative splicing can occur in different ways. The most representative mechanisms are as follows: 1, extending or shortening the exon by alternative donor and acceptor sites; 2, exon skipping; 3, mutual exon exclusion; and 4, intron retention [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>]. These mechanisms allow protein isoforms with different biological characters to be produced from single genes [<xref ref-type="bibr" rid="B1">1</xref>]. Therefore, complex transcriptomes and proteomes could be derived from a limited number of genes [<xref ref-type="bibr" rid="B4">4</xref>]. Namely, this process is an important strategy for the complicated regulation of eukaryotes, and most genes (92-95%) undergo this process [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>].</p>
      <p>Alternative splicing is regulated according to cell type, developmental stage, and disease states [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>]. Biochemical mechanisms for the recognition of splice sites are not understood clearly according to cellular conditions, but some tissue-specific factors participate in alternative splicing [<xref ref-type="bibr" rid="B4">4</xref>]. In addition, quantitative gene expression is controlled by nonsense-mediated decay mechanisms that degrade targeting mRNAs, producing nonsense mutations. Thus, truncated or erroneous proteins with abnormal functions are prevented from being expressed [<xref ref-type="bibr" rid="B9">9</xref>]. Alternative transcripts could be related to various diseases, including cancer. As many as 50% of genetic diseases of humans are related to mutations in splice site sequences and regulatory elements, such enhancers and silencers, resulting in alternative exon constitution [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>]. Recently, the SpliceDisease database, providing information for relationships among gene mutation, splicing defects, and diseases, was reported [<xref ref-type="bibr" rid="B12">12</xref>]. Especially, aberrent spliced variants are found frequently in cancer, indicating that they could play a role for the survival of cancer cells [<xref ref-type="bibr" rid="B8">8</xref>]. Alternative splicing of cancer-related genes could affect cell cycle control, signal transduction pathways, apoptosis, angiogenesis, invasion, and metastasis [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B13">13</xref>].</p>
      <p>Cancer markers allow us to determine the prognosis and therapy for cancer during the remedy of cancer. Thus, the identification of cancer markers is highlighted in the cancer research field [<xref ref-type="bibr" rid="B14">14</xref>]. Cancers result from the accumulation of complex genetic and epigenetic alterations against normal regulation. Cancerous cells grow irregularly, create malignant tumors, and move to the other parts of the body. Their alternative spliced transcripts could be detected with cryptic splicing sites. Accordingly, alternative transcripts produced by splicing events represent good candidates for cancer biomarkers [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B13">13</xref>]. In the present review, we summarize and discuss the alternative splicing events and their potential as cancer biomarkers.</p>
    </sec>
    <sec>
      <title>Genetic and Epigenetic Regulation of Alternative Splicing</title>
      <p>Alternative splicing is an essential post-transcriptional process for creating various protein isoforms from the same gene. Approximately 60% of human genes have at least one alternative splice transcript [<xref ref-type="bibr" rid="B15">15</xref>]. Alternative splicing is regulated by mutations in genetic regions [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B14">14</xref>]. Most exons are flanked by the intronic dinucleotides GT (donor site) and AG (acceptor site), which are recognized by the spliceosome (<xref ref-type="fig" rid="F1">Fig. 1A</xref>). Pre-mRNA is reconstructed only by joined exons with the removal of introns. However, mutations of these splice sites lead to aberrant splicing, producing exon skipping and different joining of exons to truncated or nonfunctional or dysfunctional proteins. It was reported that mutations of splice sites may play important roles in human disease, and longer proteins also tend to associate to various disease [<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>].</p>
      <p>In the case of the <italic>PAX6</italic> gene, a 5' splice site mutation in intron 12 induces exon skipping in relation to autosomal dominant aniridia [<xref ref-type="bibr" rid="B18">18</xref>]. In the <italic>APC</italic> gene, abnormal splicing by a 3' splice site mutation in intron 3 causes exon 4 skipping due to a frameshift in hepatoblastoma [<xref ref-type="bibr" rid="B19">19</xref>]. A mutation in intron 25 of the <italic>ABCA3</italic> gene creates novel 5' splice sites [<xref ref-type="bibr" rid="B20">20</xref>]. The spliceosome is known to recognize cryptic splice sites instead of typical splice sites. Noncanonical splice sites are GC-AG, GG-AG, GT-TG, GT-CG, AT-AG, GA-AG, GT-AC, and CT-AG (5'-3' splice sites) [<xref ref-type="bibr" rid="B21">21</xref>-<xref ref-type="bibr" rid="B23">23</xref>]. Mutations at the noncanonical splice site of the <italic>SEDL</italic> gene cause variants in X-linked spondyloepiphyseal dysplasia tarda [<xref ref-type="bibr" rid="B24">24</xref>]. Additionally, less exon skipping and more intron retention by alternative splice sites are observed in cancer tissue compared to normal tissues from an analysis of expression sequence tags (ESTs) [<xref ref-type="bibr" rid="B25">25</xref>]. As a mutation of pre-mRNA, A to I RNA editing (conversion adenosine to inosine from deamination) also affects transcriptome diversification. RNA editing has regulatory roles, such as altering splice sites and sequences necessary for recognition of the spliceosome, resulting in modulation of alternatively spliced transcripts [<xref ref-type="bibr" rid="B26">26</xref>]. The last case of alternative splicing is by cis-genomic mutations in regulatory factors, such as branch sites, exonic and intronic splicing enhancers, and silencers [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B27">27</xref>]. Pre-mRNA has exonic and intronic splicing enhancers (ESEs, ISEs) and silencers (ESSs, ISSs) that promote exon inclusion and exclusion by regulation of splice site recognition, respectively (<xref ref-type="fig" rid="F1">Fig. 1A</xref>). The arginine-serine-rich (SR) protein that binds to ESEs induces splicing via a helping assembly spliceosome by interacting with snRNP. On the contrary, heterogeneous nuclear ribonucleoprotein is bound to ESEs and ISEs and inhibits splice site recognition by blocking spliceosome assembly [<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B27">27</xref>-<xref ref-type="bibr" rid="B29">29</xref>]. Mutations in regulatory factor could disturb the binding of these spliceosome assembly-related proteins. Mutations at nucleotide positions 57 and 58 of the 174-bp-long exon 7 cause exon 7 skipping as a result of aberrant splicing by interrupted ESE-specific consensus sequences that are recognized by the SC35 and SF2/ASF SR proteins [<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B30">30</xref>]. Additionally, Ron, encoding the tyrosine kinase receptor for macrophage-stimulating protein, has alternative splice transcripts. It is regulated by overexpression of SF2/ASF binding to ESE and ISE in colon and breast cancer [<xref ref-type="bibr" rid="B31">31</xref>].</p>
      <p>Alternative splicing is also known to be affected by epigenetic regulation, such as DNA methylation, histone modification, and chromatin structure (<xref ref-type="fig" rid="F1">Fig. 1B</xref>). The relationship between chromatin structure and alternative splicing is still in a maze, but association studies are gradually increasing genomewide [<xref ref-type="bibr" rid="B32">32</xref>-<xref ref-type="bibr" rid="B34">34</xref>]. Hisone modifications are enriched in exons rather than introns and related to exon expression, especially H3K36me3, H3K79me1, H2BK5me1, H3K27me1, H3K27me2, and H3K27me3 [<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B36">36</xref>]. H3K36me3 marking in exons is found in weakly expressed, alternatively spliced exons, indicating that histone modification has a relation to transcription via splicing-related marking mechanisms [<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>]. These histone marks could recruit splicing regulators with chromatin binding proteins and affect mRNA splicing [<xref ref-type="bibr" rid="B33">33</xref>]. Additionally, hisone acethylation could modulate splicing rates to react quickly to changing conditions with increased RNA polymerase II processivity, and spliceosome rearrangements are affected by histone acetylation [<xref ref-type="bibr" rid="B38">38</xref>]. Nevertheless, although there is little evidence, DNA methylation has been reported to have a relationship with splice sites. CpG dinucleotides are distributed nonrandomly in the genome. Exon skipping and mutually exclusive exons have significantly lower levels of both CG and mCG in the exonic regions, whereas intron retention has significantly higher levels of CG in both exonic and intronic regions [<xref ref-type="bibr" rid="B34">34</xref>]. A DNA-binding protein, CCCTC-binding factor (CTCF), was inhibited by a methylation event of CD45 exon 5 [<xref ref-type="bibr" rid="B39">39</xref>]. These epigenetic features are strongly associated with alternative splicing. Furthermore, these mechanisms are known to be changed according to cell type and disease states. Especially, in cancer, the epigenetic regulation of chromatin structure effects aberrant gene expression by alternative splicing in cancer [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>].</p>
      <p>Taken together, gene expression via alternative splicing is altered by complicated and mutual mechanisms, from genetic to epigenetic regulation. Therefore, it casts light on the understanding of cancer mechanisms by an investigation of alternative splicing patterns.</p>
    </sec>
    <sec>
      <title>Alternative Splicing in Cancer</title>
      <p>A number of studies have been reported that alternative splicing is related closely to development, cellular stress, and various diseases, including cancer, as a crucial contributor to transcriptome and proteome diversity [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B14">14</xref>]. In cancer, with increasing genomic instability, sequence substitution and aberrant alternative splicing occur frequently, leading to erroneous and dysfunctional proteins [<xref ref-type="bibr" rid="B14">14</xref>]. Protein isoforms made from this process are developmentally regulated and preferentially re-expressed in cancer and help the differentiation and survival of cancer cells (<xref ref-type="fig" rid="F2">Fig. 2</xref>). The development of genomewide analysis allows large-scale examination of the relationship between alternative splicing and tumorigenesis [<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B41">41</xref>]. Every case of alternative splicing is reported in cancer; among these, the most frequent case is the mutually exclusive exon [<xref ref-type="bibr" rid="B14">14</xref>]. For example, overexpression of CD44, involved in cell proliferation, differentiation, migration, and alternative splicing, by different splice sites of CD44 during tumorigenesis indicates that it could play roles in tumor cell invasion and metastasis [<xref ref-type="bibr" rid="B42">42</xref>-<xref ref-type="bibr" rid="B45">45</xref>]. Tumor suppressor genes, such as p53 and PTEN (Phosphatase and Tensin homolog, deleted on chromosome TEN), have splicing variants associated to cancer [<xref ref-type="bibr" rid="B46">46</xref>]. p53 protein isoforms through alternative splicing have critical roles in many biological processes, indicating that dysregulation effects tumorigenesis [<xref ref-type="bibr" rid="B47">47</xref>]. Different expression of PTEN and its alternatively spliced transcripts are found to vary in different tissue types. PTEN regulates p53 stability and in turn regulates its own transcriptional activity. The PTEN splice variants retained in intron 3 region and intron 5 region have been found in breast cancer [<xref ref-type="bibr" rid="B46">46</xref>]. In the case of the <italic>APC</italic> gene, aberrant splice skipping of exon 4, created by insertion of T in intron 4, is involved in colon cancer [<xref ref-type="bibr" rid="B48">48</xref>]. An alternative 5' splice site in <italic>BCL-X</italic> results in 2 isoforms, long and short (Bcl-x (L), Bcl-x (X)), which have contrasting functions related to apoptosis and are overexpressed in various tumors [<xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B50">50</xref>]. Although specific roles of vascular endothelial growth factor (VEGF) isoforms are not known exactly, among the isoforms of VEGF4 involved in formation of new vessels, VEGF165 and VEGF165b, created by an alternative 3' splice site, have different expression in cancer [<xref ref-type="bibr" rid="B51">51</xref>, <xref ref-type="bibr" rid="B52">52</xref>]. Over 40 different MDM2 transcripts are identified in normal and cancer by alternative 5' and 3' splice sites. They mostly lose the p53 binding domain and promote tumor progression and affect prognosis independently [<xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B54">54</xref>]. Increasing number of reports have demonstrated the expression of aberrant and abnormal splice variants in cancer cells or tissues. However, it is not enough evidence for a functional relationship between alternative splicing and cancer. Hallmarks of the initiation and early growth of cancers during tumor progression using large-scale analyses of splicing variants in the cancer EST database are needed as new RNA prognosis markers.</p>
    </sec>
    <sec>
      <title>Alternative Spliced Transcripts as Cancer Biomarkers</title>
      <p>Cancer is an uncontrolled state and irregularly altered genetically and epigenetically compared to normal regulation (<xref ref-type="fig" rid="F2">Fig. 2</xref>). For this reason, many studies have made an effort to identify specific features and regulation mechanims of various diseases, including cancer. It is important and necessary to identify cancer markers to be able to distinguish between cancer and normal cells. Cancer markers could be very helpful in understanding tumorigenesis and developing tumor targets for therapeutic intervention. However, there still remain unsolved problems in spite of a number of studies [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B64">64</xref>]. From this point of view, alternatively spliced transcripts by mutation and cryptic splice site altered expression levels in cancer have emerged as strong candidates of cancer biomarker at the mRNA and protein level [<xref ref-type="bibr" rid="B7">7</xref>]. As written previously, some alternative transcripts of several genes, <italic>CD44</italic>, <italic>p53</italic>, <italic>PTEN</italic>, <italic>BCL-X</italic>, <italic>VEGF4</italic>, and <italic>MDM2</italic>, have been discovered (see also <xref ref-type="table" rid="T1">Table 1</xref>) [<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B54">54</xref>]. They are also associated with various cancers directly or indirectly. Recently, the discovery of biomarkers has improved by genomewide analysis [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B65">65</xref>, <xref ref-type="bibr" rid="B66">66</xref>]. It could be expected to provide valuable information for the association between alternative splice variants and cancers. Thus, novel candidate variants could contribute to the development of diagnostic, prognostic, and therapeutic markers.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusion</title>
      <p>RNA splicing is a core mechanism to generate mature mRNA for translation, and alternative splicing is an indispensable mechanism, stratgically leading to protein diversity for complicated regulation in eukaryotes. In cancer, alternative splicing is more flexible, leading various proteins with aberrant functions to promote growth and the spread of cancer cells. It is important to identify alternative transcripts that function specifically in cancer. These alternative transcripts could be used not only as diagnostic biomarkers but also prognostic and theraputic biomarkers. Therefore, studies on genetic and epigenetic regulation in relation to alternative splice variants in cancer could open new windows of research in answering unsolved questions of tumorigenesis.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>This work was supported by a 2-Year Research Grant of Pusan National University.</p>
    </ack>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pajares</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Ezponda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Catena</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Calvo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pio</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Montuenga</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>Alternative splicing: an emerging topic in molecular and clinical oncology</article-title>
          <source>Lancet Oncol</source>
          <year>2007</year>
          <volume>8</volume>
          <fpage>349</fpage>
          <lpage>357</lpage>
          <pub-id pub-id-type="pmid">17395108</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wahl</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Will</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>L&#xFC;hrmann</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>The spliceosome: design principles of a dynamic RNP machine</article-title>
          <source>Cell</source>
          <year>2009</year>
          <volume>136</volume>
          <fpage>701</fpage>
          <lpage>718</lpage>
          <pub-id pub-id-type="pmid">19239890</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matlin</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>CW</given-names>
            </name>
          </person-group>
          <article-title>Understanding alternative splicing: towards a cellular code</article-title>
          <source>Nat Rev Mol Cell Biol</source>
          <year>2005</year>
          <volume>6</volume>
          <fpage>386</fpage>
          <lpage>398</lpage>
          <pub-id pub-id-type="pmid">15956978</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nilsen</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Graveley</surname>
              <given-names>BR</given-names>
            </name>
          </person-group>
          <article-title>Expansion of the eukaryotic proteome by alternative splicing</article-title>
          <source>Nature</source>
          <year>2010</year>
          <volume>463</volume>
          <fpage>457</fpage>
          <lpage>463</lpage>
          <pub-id pub-id-type="pmid">20110989</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Sandberg</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Khrebtukova</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Mayr</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Alternative isoform regulation in human tissue transcriptomes</article-title>
          <source>Nature</source>
          <year>2008</year>
          <volume>456</volume>
          <fpage>470</fpage>
          <lpage>476</lpage>
          <pub-id pub-id-type="pmid">18978772</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pan</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Shai</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Frey</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Blencowe</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
          <article-title>Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing</article-title>
          <source>Nat Genet</source>
          <year>2008</year>
          <volume>40</volume>
          <fpage>1413</fpage>
          <lpage>1415</lpage>
          <pub-id pub-id-type="pmid">18978789</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brinkman</surname>
              <given-names>BM</given-names>
            </name>
          </person-group>
          <article-title>Splice variants as cancer biomarkers</article-title>
          <source>Clin Biochem</source>
          <year>2004</year>
          <volume>37</volume>
          <fpage>584</fpage>
          <lpage>594</lpage>
          <pub-id pub-id-type="pmid">15234240</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Skotheim</surname>
              <given-names>RI</given-names>
            </name>
            <name>
              <surname>Nees</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Alternative splicing in cancer: noise, functional, or systematic?</article-title>
          <source>Int J Biochem Cell Biol</source>
          <year>2007</year>
          <volume>39</volume>
          <fpage>1432</fpage>
          <lpage>1449</lpage>
          <pub-id pub-id-type="pmid">17416541</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chang</surname>
              <given-names>YF</given-names>
            </name>
            <name>
              <surname>Imam</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Wilkinson</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
          <article-title>The nonsense-mediated decay RNA surveillance pathway</article-title>
          <source>Annu Rev Biochem</source>
          <year>2007</year>
          <volume>76</volume>
          <fpage>51</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="pmid">17352659</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>C&#xE1;ceres</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Kornblihtt</surname>
              <given-names>AR</given-names>
            </name>
          </person-group>
          <article-title>Alternative splicing: multiple control mechanisms and involvement in human disease</article-title>
          <source>Trends Genet</source>
          <year>2002</year>
          <volume>18</volume>
          <fpage>186</fpage>
          <lpage>193</lpage>
          <pub-id pub-id-type="pmid">11932019</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cartegni</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chew</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Krainer</surname>
              <given-names>AR</given-names>
            </name>
          </person-group>
          <article-title>Listening to silence and understanding nonsense: exonic mutations that affect splicing</article-title>
          <source>Nat Rev Genet</source>
          <year>2002</year>
          <volume>3</volume>
          <fpage>285</fpage>
          <lpage>298</lpage>
          <pub-id pub-id-type="pmid">11967553</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>Q</given-names>
            </name>
          </person-group>
          <article-title>SpliceDisease database: linking RNA splicing and disease</article-title>
          <source>Nucleic Acids Res</source>
          <year>2012</year>
          <volume>40</volume>
          <fpage>D1055</fpage>
          <lpage>D1059</lpage>
          <pub-id pub-id-type="pmid">22139928</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Venables</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Unbalanced alternative splicing and its significance in cancer</article-title>
          <source>Bioessays</source>
          <year>2006</year>
          <volume>28</volume>
          <fpage>378</fpage>
          <lpage>386</lpage>
          <pub-id pub-id-type="pmid">16547952</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Venables</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Aberrant and alternative splicing in cancer</article-title>
          <source>Cancer Res</source>
          <year>2004</year>
          <volume>64</volume>
          <fpage>7647</fpage>
          <lpage>7654</lpage>
          <pub-id pub-id-type="pmid">15520162</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Black</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of alternative pre-messenger RNA splicing</article-title>
          <source>Annu Rev Biochem</source>
          <year>2003</year>
          <volume>72</volume>
          <fpage>291</fpage>
          <lpage>336</lpage>
          <pub-id pub-id-type="pmid">12626338</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>L&#xF3;pez-Bigas</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ouzounis</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
          <article-title>Genome-wide identification of genes likely to be involved in human genetic disease</article-title>
          <source>Nucleic Acids Res</source>
          <year>2004</year>
          <volume>32</volume>
          <fpage>3108</fpage>
          <lpage>3114</lpage>
          <pub-id pub-id-type="pmid">15181176</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>L&#xF3;pez-Bigas</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Audit</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ouzounis</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Parra</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Guig&#xF3;</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Are splicing mutations the most frequent cause of hereditary disease?</article-title>
          <source>FEBS Lett</source>
          <year>2005</year>
          <volume>579</volume>
          <fpage>1900</fpage>
          <lpage>1903</lpage>
          <pub-id pub-id-type="pmid">15792793</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weisschuh</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Wissinger</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gramer</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>A splice site mutation in the <italic>PAX6</italic> gene which induces exon skipping causes autosomal dominant inherited aniridia</article-title>
          <source>Mol Vis</source>
          <year>2012</year>
          <volume>18</volume>
          <fpage>751</fpage>
          <lpage>757</lpage>
          <pub-id pub-id-type="pmid">22509105</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kurahashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takami</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Oue</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kusafuka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Okada</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tawa</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Biallelic inactivation of the APC gene in hepatoblastoma</article-title>
          <source>Cancer Res</source>
          <year>1995</year>
          <volume>55</volume>
          <fpage>5007</fpage>
          <lpage>5011</lpage>
          <pub-id pub-id-type="pmid">7585543</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agrawal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hamvas</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cole</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>Wambach</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Wegner</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Coghill</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>An intronic <italic>ABCA3</italic> mutation that is responsible for respiratory disease</article-title>
          <source>Pediatr Res</source>
          <year>2012</year>
          <volume>71</volume>
          <fpage>633</fpage>
          <lpage>637</lpage>
          <pub-id pub-id-type="pmid">22337229</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jackson</surname>
              <given-names>IJ</given-names>
            </name>
          </person-group>
          <article-title>A reappraisal of non-consensus mRNA splice sites</article-title>
          <source>Nucleic Acids Res</source>
          <year>1991</year>
          <volume>19</volume>
          <fpage>3795</fpage>
          <lpage>3798</lpage>
          <pub-id pub-id-type="pmid">1713664</pub-id>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xue</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rask</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>The unusual 5' splicing border GC is used in myrosinase genes of the Brassicaceae</article-title>
          <source>Plant Mol Biol</source>
          <year>1995</year>
          <volume>29</volume>
          <fpage>167</fpage>
          <lpage>171</lpage>
          <pub-id pub-id-type="pmid">7579162</pub-id>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burset</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Seledtsov</surname>
              <given-names>IA</given-names>
            </name>
            <name>
              <surname>Solovyev</surname>
              <given-names>VV</given-names>
            </name>
          </person-group>
          <article-title>Analysis of canonical and non-canonical splice sites in mammalian genomes</article-title>
          <source>Nucleic Acids Res</source>
          <year>2000</year>
          <volume>28</volume>
          <fpage>4364</fpage>
          <lpage>4375</lpage>
          <pub-id pub-id-type="pmid">11058137</pub-id>
        </element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xiong</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Fang</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Noncanonical and canonical splice sites: a novel mutation at the rare noncanonical splice-donor cut site (IVS4 + 1A &gt; G) of <italic>SEDL</italic> causes variable splicing isoforms in X-linked spondyloepiphyseal dysplasia tarda</article-title>
          <source>Eur J Hum Genet</source>
          <year>2009</year>
          <volume>17</volume>
          <fpage>510</fpage>
          <lpage>516</lpage>
          <pub-id pub-id-type="pmid">19002213</pub-id>
        </element-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Goren</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ast</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Insights into the connection between cancer and alternative splicing</article-title>
          <source>Trends Genet</source>
          <year>2008</year>
          <volume>24</volume>
          <fpage>7</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="pmid">18054115</pub-id>
        </element-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dominissini</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Moshitch-Moshkovitz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Amariglio</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Rechavi</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Adenosine-to-inosine RNA editing meets cancer</article-title>
          <source>Carcinogenesis</source>
          <year>2011</year>
          <volume>32</volume>
          <fpage>1569</fpage>
          <lpage>1577</lpage>
          <pub-id pub-id-type="pmid">21715563</pub-id>
        </element-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maniatis</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tasic</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Alternative pre-mRNA splicing and proteome expansion in metazoans</article-title>
          <source>Nature</source>
          <year>2002</year>
          <volume>418</volume>
          <fpage>236</fpage>
          <lpage>243</lpage>
          <pub-id pub-id-type="pmid">12110900</pub-id>
        </element-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dreyfuss</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Matunis</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Pi&#xF1;ol-Roma</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Burd</surname>
              <given-names>CG</given-names>
            </name>
          </person-group>
          <article-title>hnRNP proteins and the biogenesis of mRNA</article-title>
          <source>Annu Rev Biochem</source>
          <year>1993</year>
          <volume>62</volume>
          <fpage>289</fpage>
          <lpage>321</lpage>
          <pub-id pub-id-type="pmid">8352591</pub-id>
        </element-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tacke</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Manley</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Functions of SR and Tra2 proteins in pre-mRNA splicing regulation</article-title>
          <source>Proc Soc Exp Biol Med</source>
          <year>1999</year>
          <volume>220</volume>
          <fpage>59</fpage>
          <lpage>63</lpage>
          <pub-id pub-id-type="pmid">9933499</pub-id>
        </element-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Colapietro</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gervasini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Natacci</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Riva</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Larizza</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title><italic>NF1</italic> exon 7 skipping and sequence alterations in exonic splice enhancers (ESEs) in a neurofibromatosis 1 patient</article-title>
          <source>Hum Genet</source>
          <year>2003</year>
          <volume>113</volume>
          <fpage>551</fpage>
          <lpage>554</lpage>
          <pub-id pub-id-type="pmid">13680360</pub-id>
        </element-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghigna</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Giordano</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Benvenuto</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Castiglioni</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Comoglio</surname>
              <given-names>PM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cell motility is controlled by SF2/ASF through alternative splicing of the <italic>Ron</italic> protooncogene</article-title>
          <source>Mol Cell</source>
          <year>2005</year>
          <volume>20</volume>
          <fpage>881</fpage>
          <lpage>890</lpage>
          <pub-id pub-id-type="pmid">16364913</pub-id>
        </element-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwartz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Meshorer</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ast</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Chromatin organization marks exon-intron structure</article-title>
          <source>Nat Struct Mol Biol</source>
          <year>2009</year>
          <volume>16</volume>
          <fpage>990</fpage>
          <lpage>995</lpage>
          <pub-id pub-id-type="pmid">19684600</pub-id>
        </element-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luco</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Pan</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Tominaga</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Blencowe</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Pereira-Smith</surname>
              <given-names>OM</given-names>
            </name>
            <name>
              <surname>Misteli</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Regulation of alternative splicing by histone modifications</article-title>
          <source>Science</source>
          <year>2010</year>
          <volume>327</volume>
          <fpage>996</fpage>
          <lpage>1000</lpage>
          <pub-id pub-id-type="pmid">20133523</pub-id>
        </element-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhou</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Epigenetic features are significantly associated with alternative splicing</article-title>
          <source>BMC Genomics</source>
          <year>2012</year>
          <volume>13</volume>
          <fpage>123</fpage>
          <pub-id pub-id-type="pmid">22455468</pub-id>
        </element-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andersson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Enroth</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rada-Iglesias</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wadelius</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Komorowski</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Nucleosomes are well positioned in exons and carry characteristic histone modifications</article-title>
          <source>Genome Res</source>
          <year>2009</year>
          <volume>19</volume>
          <fpage>1732</fpage>
          <lpage>1741</lpage>
          <pub-id pub-id-type="pmid">19687145</pub-id>
        </element-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kolasinska-Zwierz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Down</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Latorre</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>XS</given-names>
            </name>
            <name>
              <surname>Ahringer</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Differential chromatin marking of introns and expressed exons by H3K36me3</article-title>
          <source>Nat Genet</source>
          <year>2009</year>
          <volume>41</volume>
          <fpage>376</fpage>
          <lpage>381</lpage>
          <pub-id pub-id-type="pmid">19182803</pub-id>
        </element-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wilhelm</surname>
              <given-names>BT</given-names>
            </name>
            <name>
              <surname>Marguerat</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Aligianni</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Codlin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Watt</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>B&#xE4;hler</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Differential patterns of intronic and exonic DNA regions with respect to RNA polymerase II occupancy, nucleosome density and H3K36me3 marking in fission yeast</article-title>
          <source>Genome Biol</source>
          <year>2011</year>
          <volume>12</volume>
          <fpage>R82</fpage>
          <pub-id pub-id-type="pmid">21859475</pub-id>
        </element-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gunderson</surname>
              <given-names>FQ</given-names>
            </name>
            <name>
              <surname>Merkhofer</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>TL</given-names>
            </name>
          </person-group>
          <article-title>Dynamic histone acetylation is critical for cotranscriptional spliceosome assembly and spliceosomal rearrangements</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2011</year>
          <volume>108</volume>
          <fpage>2004</fpage>
          <lpage>2009</lpage>
          <pub-id pub-id-type="pmid">21245291</pub-id>
        </element-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shukla</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kavak</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gregory</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Imashimizu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shutinoski</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kashlev</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing</article-title>
          <source>Nature</source>
          <year>2011</year>
          <volume>479</volume>
          <fpage>74</fpage>
          <lpage>79</lpage>
          <pub-id pub-id-type="pmid">21964334</pub-id>
        </element-citation>
      </ref>
      <ref id="B40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>David</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Manley</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged</article-title>
          <source>Genes Dev</source>
          <year>2010</year>
          <volume>24</volume>
          <fpage>2343</fpage>
          <lpage>2364</lpage>
          <pub-id pub-id-type="pmid">21041405</pub-id>
        </element-citation>
      </ref>
      <ref id="B41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Venables</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Klinck</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Koh</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gervais-Bird</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bramard</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Inkel</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cancer-associated regulation of alternative splicing</article-title>
          <source>Nat Struct Mol Biol</source>
          <year>2009</year>
          <volume>16</volume>
          <fpage>670</fpage>
          <lpage>676</lpage>
          <pub-id pub-id-type="pmid">19448617</pub-id>
        </element-citation>
      </ref>
      <ref id="B42">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stickeler</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kittrell</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Medina</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Berget</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis</article-title>
          <source>Oncogene</source>
          <year>1999</year>
          <volume>18</volume>
          <fpage>3574</fpage>
          <lpage>3582</lpage>
          <pub-id pub-id-type="pmid">10380879</pub-id>
        </element-citation>
      </ref>
      <ref id="B43">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Naor</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Nedvetzki</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Golan</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Melnik</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Faitelson</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>CD44 in cancer</article-title>
          <source>Crit Rev Clin Lab Sci</source>
          <year>2002</year>
          <volume>39</volume>
          <fpage>527</fpage>
          <lpage>579</lpage>
          <pub-id pub-id-type="pmid">12484499</pub-id>
        </element-citation>
      </ref>
      <ref id="B44">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Faustino</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>TA</given-names>
            </name>
          </person-group>
          <article-title>Pre-mRNA splicing and human disease</article-title>
          <source>Genes Dev</source>
          <year>2003</year>
          <volume>17</volume>
          <fpage>419</fpage>
          <lpage>437</lpage>
          <pub-id pub-id-type="pmid">12600935</pub-id>
        </element-citation>
      </ref>
      <ref id="B45">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalnina</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zayakin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Silina</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lin&#x113;</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Alterations of pre-mRNA splicing in cancer</article-title>
          <source>Genes Chromosomes Cancer</source>
          <year>2005</year>
          <volume>42</volume>
          <fpage>342</fpage>
          <lpage>357</lpage>
          <pub-id pub-id-type="pmid">15648050</pub-id>
        </element-citation>
      </ref>
      <ref id="B46">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Okumura</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kitagishi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nishimura</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Matsuda</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Alternative splicings on <italic>p53</italic>, <italic>BRCA1</italic> and <italic>PTEN</italic> genes involved in breast cancer</article-title>
          <source>Biochem Biophys Res Commun</source>
          <year>2011</year>
          <volume>413</volume>
          <fpage>395</fpage>
          <lpage>399</lpage>
          <pub-id pub-id-type="pmid">21893034</pub-id>
        </element-citation>
      </ref>
      <ref id="B47">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wei</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zaika</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Zaika</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>p53 family: role of protein isoforms in human cancer</article-title>
          <source>J Nucleic Acids</source>
          <year>2012</year>
          <volume>2012</volume>
          <fpage>687359</fpage>
          <pub-id pub-id-type="pmid">22007292</pub-id>
        </element-citation>
      </ref>
      <ref id="B48">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neklason</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Solomon</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Dalton</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Kuwada</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Burt</surname>
              <given-names>RW</given-names>
            </name>
          </person-group>
          <article-title>Intron 4 mutation in <italic>APC</italic> gene results in splice defect and attenuated FAP phenotype</article-title>
          <source>Fam Cancer</source>
          <year>2004</year>
          <volume>3</volume>
          <fpage>35</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="pmid">15131404</pub-id>
        </element-citation>
      </ref>
      <ref id="B49">
        <label>49</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olopade</surname>
              <given-names>OI</given-names>
            </name>
            <name>
              <surname>Adeyanju</surname>
              <given-names>MO</given-names>
            </name>
            <name>
              <surname>Safa</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Hagos</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mick</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>CB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases</article-title>
          <source>Cancer J Sci Am</source>
          <year>1997</year>
          <volume>3</volume>
          <fpage>230</fpage>
          <lpage>237</lpage>
          <pub-id pub-id-type="pmid">9263629</pub-id>
        </element-citation>
      </ref>
      <ref id="B50">
        <label>50</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takehara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Fujimoto</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Friedman</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Expression and role of Bcl-xL in human hepatocellular carcinomas</article-title>
          <source>Hepatology</source>
          <year>2001</year>
          <volume>34</volume>
          <fpage>55</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="pmid">11431734</pub-id>
        </element-citation>
      </ref>
      <ref id="B51">
        <label>51</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Woolard</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>WY</given-names>
            </name>
            <name>
              <surname>Bevan</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Qiu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Morbidelli</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pritchard-Jones</surname>
              <given-names>RO</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, <italic>in vivo</italic> effect on angiogenesis and endogenous protein expression</article-title>
          <source>Cancer Res</source>
          <year>2004</year>
          <volume>64</volume>
          <fpage>7822</fpage>
          <lpage>7835</lpage>
          <pub-id pub-id-type="pmid">15520188</pub-id>
        </element-citation>
      </ref>
      <ref id="B52">
        <label>52</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pritchard-Jones</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Dunn</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Qiu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Varey</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Orlando</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rigby</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma</article-title>
          <source>Br J Cancer</source>
          <year>2007</year>
          <volume>97</volume>
          <fpage>223</fpage>
          <lpage>230</lpage>
          <pub-id pub-id-type="pmid">17595666</pub-id>
        </element-citation>
      </ref>
      <ref id="B53">
        <label>53</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bartel</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Taubert</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>LC</given-names>
            </name>
          </person-group>
          <article-title>Alternative and aberrant splicing of MDM2 mRNA in human cancer</article-title>
          <source>Cancer Cell</source>
          <year>2002</year>
          <volume>2</volume>
          <fpage>9</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="pmid">12150820</pub-id>
        </element-citation>
      </ref>
      <ref id="B54">
        <label>54</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bartel</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Wurl</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Taubert</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>MDM2 and its splice variant messenger RNAs: expression in tumors and down-regulation using antisense oligonucleotides</article-title>
          <source>Mol Cancer Res</source>
          <year>2004</year>
          <volume>2</volume>
          <fpage>29</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="pmid">14757843</pub-id>
        </element-citation>
      </ref>
      <ref id="B55">
        <label>55</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arvanitis</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Lianos</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Soulitzis</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Delakas</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Spandidos</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Deregulation of p73 isoform equilibrium in benign prostate hyperplasia and prostate cancer</article-title>
          <source>Oncol Rep</source>
          <year>2004</year>
          <volume>12</volume>
          <fpage>1131</fpage>
          <lpage>1137</lpage>
          <pub-id pub-id-type="pmid">15492805</pub-id>
        </element-citation>
      </ref>
      <ref id="B56">
        <label>56</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Line</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Slucka</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Stengrevics</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rees</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>Altered splicing pattern of TACC1 mRNA in gastric cancer</article-title>
          <source>Cancer Genet Cytogenet</source>
          <year>2002</year>
          <volume>139</volume>
          <fpage>78</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="pmid">12547166</pub-id>
        </element-citation>
      </ref>
      <ref id="B57">
        <label>57</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kotoula</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Barbanis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nikolakaki</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Koufoyannis</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Papadimitriou</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Karkavelas</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Relative expression of human telomerase catalytic subunit (hTERT) transcripts in astrocytic gliomas</article-title>
          <source>Acta Neuropathol</source>
          <year>2004</year>
          <volume>107</volume>
          <fpage>443</fpage>
          <lpage>451</lpage>
          <pub-id pub-id-type="pmid">14986029</pub-id>
        </element-citation>
      </ref>
      <ref id="B58">
        <label>58</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>DiFeo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Martignetti</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Narla</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>The role of KLF6 and its splice variants in cancer therapy</article-title>
          <source>Drug Resist Updat</source>
          <year>2009</year>
          <volume>12</volume>
          <fpage>1</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">19097929</pub-id>
        </element-citation>
      </ref>
      <ref id="B59">
        <label>59</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Role of survivin and its splice variants in tumorigenesis</article-title>
          <source>Br J Cancer</source>
          <year>2005</year>
          <volume>92</volume>
          <fpage>212</fpage>
          <lpage>216</lpage>
          <pub-id pub-id-type="pmid">15611788</pub-id>
        </element-citation>
      </ref>
      <ref id="B60">
        <label>60</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>The effect of isoforms of the cell polarity protein, human ASIP, on the cell cycle and Fas/FasL-mediated apoptosis in human hepatoma cells</article-title>
          <source>Cell Mol Life Sci</source>
          <year>2005</year>
          <volume>62</volume>
          <fpage>1974</fpage>
          <lpage>1983</lpage>
          <pub-id pub-id-type="pmid">16091846</pub-id>
        </element-citation>
      </ref>
      <ref id="B61">
        <label>61</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barron</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Lou</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Alternative splicing of the neurofibromatosis type I pre-mRNA</article-title>
          <source>Biosci Rep</source>
          <year>2012</year>
          <volume>32</volume>
          <fpage>131</fpage>
          <lpage>138</lpage>
          <pub-id pub-id-type="pmid">22115364</pub-id>
        </element-citation>
      </ref>
      <ref id="B62">
        <label>62</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mohr</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zwacka</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Jarmy</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>B&#xFC;neker</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schrezenmeier</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>D&#xF6;hner</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis</article-title>
          <source>Oncogene</source>
          <year>2005</year>
          <volume>24</volume>
          <fpage>2421</fpage>
          <lpage>2429</lpage>
          <pub-id pub-id-type="pmid">15735742</pub-id>
        </element-citation>
      </ref>
      <ref id="B63">
        <label>63</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>XQ</given-names>
            </name>
            <name>
              <surname>Luk</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Leung</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Stanbridge</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>ST</given-names>
            </name>
          </person-group>
          <article-title>Alternative mRNA splicing of liver intestine-cadherin in hepatocellular carcinoma</article-title>
          <source>Clin Cancer Res</source>
          <year>2005</year>
          <volume>11</volume>
          <issue>2 Pt 1</issue>
          <fpage>483</fpage>
          <lpage>489</lpage>
          <pub-id pub-id-type="pmid">15701831</pub-id>
        </element-citation>
      </ref>
      <ref id="B64">
        <label>64</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pettigrew</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Pre-mRNA splicing aberrations and cancer</article-title>
          <source>Front Biosci</source>
          <year>2008</year>
          <volume>13</volume>
          <fpage>1090</fpage>
          <lpage>1105</lpage>
          <pub-id pub-id-type="pmid">17981615</pub-id>
        </element-citation>
      </ref>
      <ref id="B65">
        <label>65</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cuperlovic-Culf</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Belacel</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Culf</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Ouellette</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Data analysis of alternative splicing microarrays</article-title>
          <source>Drug Discov Today</source>
          <year>2006</year>
          <volume>11</volume>
          <fpage>983</fpage>
          <lpage>990</lpage>
          <pub-id pub-id-type="pmid">17055407</pub-id>
        </element-citation>
      </ref>
      <ref id="B66">
        <label>66</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Omenn</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Yocum</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Menon</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Alternative splice variants, a new class of protein cancer biomarker candidates: findings in pancreatic cancer and breast cancer with systems biology implications</article-title>
          <source>Dis Markers</source>
          <year>2010</year>
          <volume>28</volume>
          <fpage>241</fpage>
          <lpage>251</lpage>
          <pub-id pub-id-type="pmid">20534909</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Fig. 1</label>
      <caption>
        <p>Genetic and epigenetic regulation of alternative splicing. (A) Most genes are spliced by typical splice sites (GT-AG) and regulatory sequences in exons (ESS and ESE) and introns (ISS and ISE). Mutations (<sup>*</sup>) generate alternative splicing, resulting in various transcripts from a single gene. (B) H3K36me3 marking in exons is found in weakly expressed alternatively spliced exons (grey thin dotted line), and H3K4me3 marks are rich in spliced exons (black thick dotted line), indicating that histone modification has a relation to transcription via splicing-related marking mechanisms. Additionally, hisone acethylation could modulate splicing rates to react quickly to changing conditions with increased RNA polymerase II processivity, and spliceosome rearrangements are affected by histone acetylation. High levels of CG have a tendency not to be spliced (grey line in intron), and exon skipping is in the lower level of both CG and mCG in exonic regions. Methylation of exon inhibits binding of CCCTC-binding factor (CTCF), leading to exon skipping. ESE, exonic splicing enhancers; ISE, intronic splicing enhancers; ESS, exonic and intronic splicing silencers; ISS, intronic splicing silencers; SR, arginine-serine-rich; RNP, ribonucleoprotein.</p>
      </caption>
      <graphic xlink:href="gni-10-74-g001"/>
    </fig>
    <fig id="F2" position="float">
      <label>Fig. 2</label>
      <caption>
        <p>Roles of alternative splicing in cancer. Dysfunctional proteins are generated by alternative splicing in cancer-related genes (oncogenic and tumor suppressor genes), increasing genomic instability. These aberrant proteins help cancerous cells to promote their growth, proliferation, and metastasis continuously (tumorigenesis). Variants of cancer-related genes expressed specifically or differently with their crucial roles for tumorigenesis could be potential biomarkers to distinguish between normal and cancer cells.</p>
      </caption>
      <graphic xlink:href="gni-10-74-g002"/>
    </fig>
    <table-wrap id="T1" position="float">
      <label>Table 1</label>
      <caption>
        <p>Alternative spliced transcript related to cancer</p>
      </caption>
      <graphic xlink:href="gni-10-74-i001"/>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>